Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

Gheath Alatrash, Maher Albitar, Susan O'Brien, Xuemei Wang, Taghi Manshouri, Stefan Faderl, Alessandra Ferrajoli, Jan Burger, Guillermo Garcia-Manero, Hagop M. Kantarjian, Susan Lerner, Michael J. Keating, William G. Wierda

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)'. Together they form a unique fingerprint.

Medicine & Life Sciences